Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanofi R&D CSF1R compound 36
- Development stage
- Unknown
- Lead developer
- Sanofi
01
Overview
Sanofi R&D CSF1R compound 36: sourced facts only. name: "Initial structure-activity relationship studies culminated in the identification of 36, a lead compound with potent CSF1R biochemical and cellular activity, acceptable in vitro ADME properties, and oral exposure in rat." [PMID:38746878]; target: "Initial structure-activity relationship studies culminated in the identification of 36, a lead compound with potent CSF1R biochemical and cellular activity, acceptable in vitro ADME properties, and oral exposure in rat." [PMID:38746878]; developer: "Integrated Drug Discovery, Sanofi R&D, 350 Water Street, Cambridge, Massachusetts 02141, United States." [PMID:38746878]
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on Sanofi R&D CSF1R compound 36.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanofi R&D CSF1R compound 36.